The global drug eluting stent market size was valued at USD 5.63 Billion in 2023 and is expected to reach USD 8.74 Billion by year 2032, at a CAGR of 5.67%. The development of stents has been a major advancement in the treatment of obstructive coronary artery disease since the introduction of balloon angioplasty. Stents are small mesh tubes inserted to keep arteries open after a procedure called angioplasty (percutaneous coronary intervention or PCI). Drug eluting stents (DES) have a polymer coating over mesh that emits a drug over time to help keep the blockage from coming back. These stents were introduced primarily to overcome the problem of late restenosis that was prevalent at an excessively high rate with bare-metal stents. Since the arrival of DES, restenosis figures have dropped to a single digit, even for the most complex lesions. Number of companies in the global drug eluting stent market are engaged in the launch of new DES devices.
There global drug eluting stent market trends in the report consider different strategic developments such as agreement and product development in the analysis. For instance, companies such as Biosensors and Abbott are developing biodegradable and bifurcated stents to deal with concerns about thrombosis caused by long-term device implantation and to expand the type of treatable lesions, including those located at vessel branches. The global DES market is propelled by number of factors such as rise in the geriatric population, increasing prevalence of cardiovascular diseases, growing acceptance for minimally invasive endovascular surgeries. New product developments in DES, such as biodegradable materials and bifurcated stents, are expected to prompt an increase in market value during the forecast period in the drug eluting stent market.
Request a Sample@ https://www.qyresearchmedical.com/sample/119299
Key Coverage of the Report
- Region and country-wise assessment from the period 2023-2032. For the study, 2023-2017 has been utilized as historical data, 2018 as the base year, and 2019-2032, has been derived as forecasts
- Regional Competitors pipeline analysis
- Drug eluting stent market share analysis of the key industry players
- Drug eluting stent market forecasts for a minimum of 6 years of all the mentioned segments, and the regional markets
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments.
Salient Trends of the Drug Eluting Stent Market
- Drug eluting stents are metal stents that are coated with a pharmacologic agent that is known to suppress restenosis (the reblocking or closing up of an artery after angioplasty due to excess growth inside or at the edge of the stent). One of the major objectives of drug eluting stents is to limit neointimal hyperplasia. Recently, Medtronic announced the U.S. Food and Drug Administration (FDA) approval and U.S. launch of the Resolute Onyx (TM) 2.0 mm Drug-Eluting Stent (DES) – the smallest sized DES on the market.
- The ideal DES system should have characteristics such as a very low-profile stent delivery system, High flexibility and conformability due to a hybrid open-cell design, thinner struts, adequate radiopacity and radial strength, high-pressure balloon that is suitable for direct stenting, minimal late loss (≤0.2 mm).
- There are three main components to a DES – the metal stent structure also called the stent platform which is generally made up of surgical stainless steel or a cobalt chromium alloy; these all contain nickel. The polymer which coats the metal stent: this coating contains the drug and delivers (elutes) it to the arterial wall over a period of time. The drug itself which suppresses the formation of excess tissue, sometimes known as “scar tissue”.
- After receiving a DES, in addition to aspirin, the patient must take a second anti-clotting or antiplatelet drug, such as clopidogrel (Plavix), prasugrel (Effient), ticagrelor (Brilinta) or ticlopidine (Ticlid).
- DES systems reduce restenosis approximately by 50% to 60%. Typically, DES are metal stents that are covered with a polymer film loaded with anti-inflammatory or antiproliferative therapeutics that are released in a sustained manner. However, although favorable effects of the released therapeutic have been observed, the polymer coating as such has been associated with several adverse clinical effects, such as late stent thrombosis.
- Polymer coating can be conformal, inhibiting smooth cell proliferation over the entire surface of the stent, or abluminal, i.e. the release of the therapeutic only has an effect on the surface in contact with the vessel wall
- Inflammatory issues caused by the polymers used in stents can be avoided by eliminating the polymer coating completely and releasing the antiproliferative therapeutic directly from the stent surface
- Various kinds of technologies have been developed to design polymer-free DES, such as the use of microporous stents and inorganic coatings that can be loaded with the appropriate therapeutic agent. Numerous agents, including sirolimus, tacrolimus, paclitaxel, and probucol have been used in the design of carrier-free stents. Due to the function of the polymeric coating to control the release kinetics of a therapeutics, polymer-free stents are anticipated to have a faster drug elution rate, which may affect the therapeutic efficacy. With no polymer or pores to control drug-release, the release rate is determined solely by the solubility and diffusion coefficient of the therapeutic in the release medium and by the thickness of the coating
- There are two major types of polymer-based coatings considered in the global drug eluting stent market, namely, biodegradable and non-biodegradable polymer. Microporous surface, microstructured surface, slotted tubular surface, and nanoporous surface are types of polymer free coating
- Peripheral arterial disease is generally caused by atherosclerosis of the main vessels supplying the lower extremities.
- Strict regulatory approval process and lack of skilled professionals are major challenges faced by the global drug eluting market
Companies considered and profiled in this market study
The companies considered in DES market analysis include, Terumo Corporation, Biosensors, Abbott Laboratories, Boston Scientific Corporation, Medtronic PLC, Biotronik SE & Co. KG, and MicroPort Scientific Corporation
- Coronary artery disease (heart disease) accounts for the highest number of deaths in America, affecting more than 13 million people. Every year, nearly 610,000 people die of heart disease in the United States; 1 in every 4 deaths
- On the basis of coating, polymer free coating stents segment is anticipated to dominate the global drug eluting stent market due to higher drug loading capacity of nanoporous surfaces, quicker drug eluting rate
- On the basis of applications, coronary artery disease is expected to be the largest segment in the global drug eluting stent market because of rise in the circulation of c reactive proteins, binge drinking and smoking
- Asia Pacific is projected to be the fastest growing segment in the global drug eluting market due to better medical facilities, government funding large population, increasing patient awareness, continuous improvement in healthcare facilities.
- North America is anticipated to have the largest share (42%) in the global drug eluting market due to increasing prevalence of artery diseases, strict regulatory guidelines for medical device manufacturing and approval related to the commercial availability of the products.
- The benefits such as availability of surgery specialists, reduced hospital stay duration, and less charge of surgery have made ambulatory surgical centers the ideal option for the treatment which is anticipated to result in ambulatory surgical centers occupying a significant market share in the global DES market during the forecast period.
Segments covered in the report
This report forecasts revenue growth at a global, regional & country level, and provides an analysis of the market trends in each of the sub-segments from 2023 to 2032. For the purpose of this study,have segmented the Drug Eluting Stent Market on the basis of coating, application, end use, and region:
Drug Eluting Stent Market, by Coating (Revenue, USD Million; 2023–2032)
- Polymer based coating
- Polymer free coating
- Microporous Surface
- Microstructured Surface
- Slotted Tubular Surface
- Nanoporous Surface
Drug Eluting Stent Market, by Application (Revenue, USD Million; 2023–2032)
- Coronary Artery Disease
- Peripheral Artery Disease
Drug Eluting Stent Market, by End Use (Revenue, USD Million; 2023–2032)
- Cardiology Centers
- Ambulatory Surgical Centers
Drug Eluting Stent Market, by Regional Outlook (Revenue in USD Million; 2023–2032)
- North America
- Rest of the Europe
- Asia Pacific
- Rest of Asia-Pacific
- Middle East & Africa
- Latin America
Buy quantitative research Report at discounted price – USD 1500 https://www.qyresearchmedical.com/report/checkout/119299/1500
You can place an order or ask any questions, please feel free to contact email@example.com | +1 9197 992 333
QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover North America, Europe, Latin America, Middle East and Africa, Asia- Pacific.
For Latest Update Follow Us: